TdaP Booster Vaccine Adjuvant Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TdaP booster vaccines for diphtheria, tetanus, and pertussis have lower antigen doses and altered antigen ratios compared to pediatric vaccines, requiring higher doses and potentially less effective immune responses in adolescents and adults.
Innovation Solution
Incorporating a TLR agonist and an oil-in-water emulsion adjuvant into TdaP vaccines to enhance immune response with reduced antigen and adjuvant amounts, while maintaining immunogenicity, by using a composition with an excess of tetanus toxoid relative to diphtheria toxoid and including inactivated poliovirus components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If lower antigen doses are used in TdaP booster vaccines compared to pediatric vaccines, then the vaccine is suitable for adolescent and adult booster immunisation, but the immune response may be less effective
Solution Approach 1:
The patent changes the adjuvant parameters by incorporating TLR agonists (such as MPL, CpG, or LPS) and oil-in-water emulsions (such as MF59 or AS03) into the vaccine formulation. These adjuvant parameter changes enhance the immunogenicity of lower antigen doses, allowing effective booster responses in adolescents and adults without requiring pediatric-level antigen quantities
Solution Approach 2:
The patent creates a composite adjuvant system combining multiple components: aluminium salts (traditional adjuvant), TLR agonists (immunostimulants), and oil-in-water emulsions (scaffold adjuvants). This composite material approach synergistically enhances immune response to low-dose antigens, resolving the contradiction between reduced antigen quantity and maintained immunogenicity
2Quantity of substance
If altered antigen ratios are used in TdaP vaccines (1:2 or 1:2.5 diphtheria:tetanus) compared to pediatric vaccines (2.5:1 or 3:1), then the vaccine composition is optimized for booster immunisation, but the diphtheria toxoid dose is significantly reduced
Solution Approach 1:
The patent applies parameter changes to the adjuvant system to compensate for reduced diphtheria toxoid doses. By incorporating TLR agonists and oil-in-water emulsions, the vaccine achieves enhanced immunogenicity that offsets the lower antigen quantity, maintaining protective immunity despite the altered antigen ratio and reduced diphtheria component
Solution Approach 2:
The patent introduces adjuvants as intermediary substances that mediate between the reduced antigen dose and the desired immune response. The TLR agonists and oil-in-water emulsions act as intermediaries that amplify the immunogenic signal from low-dose diphtheria toxoid, enabling effective protection without requiring high antigen quantities
3Reliability
If higher antigen doses are used to achieve effective immune response, then protection is stronger, but more vaccine components are required
Solution Approach 1:
The patent fundamentally changes the adjuvant parameters by incorporating immunostimulant TLR agonists and oil-in-water emulsion systems. These parameter changes enable the vaccine to achieve stronger immune responses with lower antigen doses, effectively inverting the traditional relationship where higher doses were needed for stronger responses
Solution Approach 2:
The patent skips the traditional approach of simply increasing antigen dose to enhance immunity. Instead, it rushes through to a more efficient solution by implementing advanced adjuvant technology that achieves enhanced immunogenicity through qualitative adjuvant improvements rather than quantitative antigen increases
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides stronger, longer-lasting protection with lower antigen and adjuvant doses, improving immunogenicity and reducing the amount of vaccine components needed, making it suitable for booster vaccinations in adolescents and adults.
Implementation Method 1
a TLR agonist, wherein the composition includes an excess of tetanus toxoid relative to diphtheria toxoid (in Lf units)
Implementation Method 2
All of these vaccines include an aluminium salt adjuvant
Implementation Method 3
improves current TdaP vaccines by adjuvanting them with an oil-in-water emulsion
Data Source
AI summary
The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.